vs
ENANTA PHARMACEUTICALS INC（ENTA）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是ENANTA PHARMACEUTICALS INC的1.1倍（$19.6M vs $18.6M），ENANTA PHARMACEUTICALS INC净利率更高（-64.1% vs -177.4%，领先113.3%），ENANTA PHARMACEUTICALS INC同比增速更快（9.8% vs -11.5%），ENANTA PHARMACEUTICALS INC自由现金流更多（$-11.8M vs $-23.1M），过去两年ENANTA PHARMACEUTICALS INC的营收复合增速更高（4.5% vs -12.2%）
Enanta制药是一家临床阶段生物技术企业，专注于研发针对乙型肝炎病毒、呼吸道合胞病毒、新冠病毒等传染性疾病的创新抗病毒疗法，与全球制药伙伴合作推进小分子候选药物管线，满足未被覆盖的临床需求。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
ENTA vs LAB — 直观对比
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.6M | $19.6M |
| 净利润 | $-11.9M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | -60.5% | -168.5% |
| 净利率 | -64.1% | -177.4% |
| 营收同比 | 9.8% | -11.5% |
| 净利润同比 | 46.4% | -28.8% |
| 每股收益（稀释后） | $-0.42 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $18.6M | — | ||
| Q3 25 | $15.1M | $19.6M | ||
| Q2 25 | $18.3M | $21.8M | ||
| Q1 25 | $14.9M | $40.8M | ||
| Q4 24 | $17.0M | — | ||
| Q3 24 | $14.6M | $22.1M | ||
| Q2 24 | $18.0M | $22.5M | ||
| Q1 24 | $17.1M | $45.5M |
| Q4 25 | $-11.9M | — | ||
| Q3 25 | $-18.7M | $-34.7M | ||
| Q2 25 | $-18.3M | $-33.5M | ||
| Q1 25 | $-22.6M | $-26.0M | ||
| Q4 24 | $-22.3M | — | ||
| Q3 24 | $-28.8M | $-26.9M | ||
| Q2 24 | $-22.7M | $-45.7M | ||
| Q1 24 | $-31.2M | $-32.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
| Q4 25 | -60.5% | — | ||
| Q3 25 | -121.6% | -168.5% | ||
| Q2 25 | -103.2% | -118.1% | ||
| Q1 25 | -164.3% | -80.8% | ||
| Q4 24 | -138.8% | — | ||
| Q3 24 | -204.4% | -120.9% | ||
| Q2 24 | -134.6% | -134.5% | ||
| Q1 24 | -192.1% | -132.2% |
| Q4 25 | -64.1% | — | ||
| Q3 25 | -123.6% | -177.4% | ||
| Q2 25 | -99.7% | -153.7% | ||
| Q1 25 | -151.7% | -63.8% | ||
| Q4 24 | -131.4% | — | ||
| Q3 24 | -197.3% | -122.0% | ||
| Q2 24 | -126.1% | -203.3% | ||
| Q1 24 | -182.7% | -70.6% |
| Q4 25 | $-0.42 | — | ||
| Q3 25 | $-0.88 | $-0.09 | ||
| Q2 25 | $-0.85 | $-0.09 | ||
| Q1 25 | $-1.06 | $-0.07 | ||
| Q4 24 | $-1.05 | — | ||
| Q3 24 | $-1.36 | $-0.07 | ||
| Q2 24 | $-1.07 | $-0.12 | ||
| Q1 24 | $-1.47 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.4M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $126.6M | $399.7M |
| 总资产 | $329.5M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $37.4M | — | ||
| Q3 25 | $32.3M | $129.4M | ||
| Q2 25 | $44.8M | $158.6M | ||
| Q1 25 | $60.2M | $150.9M | ||
| Q4 24 | $84.3M | — | ||
| Q3 24 | $37.2M | $210.6M | ||
| Q2 24 | $35.8M | $269.8M | ||
| Q1 24 | $63.5M | $287.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
| Q4 25 | $126.6M | — | ||
| Q3 25 | $64.7M | $399.7M | ||
| Q2 25 | $79.3M | $424.5M | ||
| Q1 25 | $93.5M | $454.6M | ||
| Q4 24 | $111.8M | — | ||
| Q3 24 | $128.8M | $489.3M | ||
| Q2 24 | $148.9M | $510.3M | ||
| Q1 24 | $166.1M | $577.3M |
| Q4 25 | $329.5M | — | ||
| Q3 25 | $280.7M | $539.6M | ||
| Q2 25 | $301.0M | $557.0M | ||
| Q1 25 | $323.0M | $579.6M | ||
| Q4 24 | $348.6M | — | ||
| Q3 24 | $376.7M | $681.5M | ||
| Q2 24 | $398.8M | $708.7M | ||
| Q1 24 | $413.6M | $777.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.7M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-11.8M | $-23.1M |
| 自由现金流率自由现金流/营收 | -63.6% | -118.1% |
| 资本支出强度资本支出/营收 | 0.8% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $-111.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-11.7M | — | ||
| Q3 25 | $-6.5M | $-22.2M | ||
| Q2 25 | $17.5M | $-20.7M | ||
| Q1 25 | $-13.5M | $-30.3M | ||
| Q4 24 | $-16.8M | — | ||
| Q3 24 | $-10.4M | $-27.9M | ||
| Q2 24 | $-14.8M | $-39.0M | ||
| Q1 24 | $-28.6M | $-62.5M |
| Q4 25 | $-11.8M | — | ||
| Q3 25 | $-7.9M | $-23.1M | ||
| Q2 25 | $17.4M | $-22.6M | ||
| Q1 25 | $-16.0M | $-35.3M | ||
| Q4 24 | $-25.5M | — | ||
| Q3 24 | $-19.4M | $-30.1M | ||
| Q2 24 | $-21.3M | $-41.0M | ||
| Q1 24 | $-30.3M | $-63.3M |
| Q4 25 | -63.6% | — | ||
| Q3 25 | -52.5% | -118.1% | ||
| Q2 25 | 94.7% | -103.6% | ||
| Q1 25 | -107.4% | -86.6% | ||
| Q4 24 | -150.6% | — | ||
| Q3 24 | -132.5% | -136.4% | ||
| Q2 24 | -118.6% | -182.2% | ||
| Q1 24 | -177.5% | -138.9% |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 9.6% | 4.5% | ||
| Q2 25 | 0.8% | 8.7% | ||
| Q1 25 | 17.0% | 12.4% | ||
| Q4 24 | 51.6% | — | ||
| Q3 24 | 61.3% | 10.2% | ||
| Q2 24 | 36.4% | 8.6% | ||
| Q1 24 | 9.8% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENTA
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
